ITFG1: A Potential Drug Target and Biomarker (G81533)

Target Name: ITFG1

NCBI ID: G81533

ITFG1

ITFG1: A Potential Drug Target and Biomarker

ITFG1, or Integrin-alpha FG-GAP repeat-containing protein 1, is a protein that has been identified as a potential drug target or biomarker. The ITFG1 gene is located on chromosome 16 and encodes a protein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract.

The protein encoded by the ITFG1 gene is composed of two distinct domains: an integrin-like alpha chain and a GAP-like beta chain. The integrin-like alpha chain consists of a variable region that includes a putative heparan sulfate (HS) anchor and a cytoplasmic domain that is involved in cell adhesion and migration. The GAP-like beta chain consists of a catalytic domain and a 250-amino acid tail that is involved in G protein-coupled receptor (GPCR) signaling.

ITFG1 is a protein that has been shown to play a role in various physiological processes, including cell adhesion, migration, and GPCR signaling. It is also expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Drug Targeting

ITFG1 has been identified as a potential drug target due to its involvement in GPCR signaling. GPCR signaling is a signaling pathway that is involved in various physiological processes, including sensory perception, neurotransmission, and cancer growth. ITFG1 has been shown to play a role in GPCR signaling by regulating the activity of several GPCRs, including the androgen receptor (AR), the insulin receptor (IR), and the 5-HT7 receptor (5-HT7R).

In addition to its role in GPCR signaling, ITFG1 has also been shown to play a role in cell adhesion and migration. ITFG1 has been shown to be involved in the regulation of cell-cell adhesion by interacting with the protein E-cadherin. It has also been shown to be involved in the regulation of cell migration by interacting with the protein FAK.

Biomarker

ITFG1 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, ITFG1 has been shown to be involved in the regulation of cancer cell growth and has been used as a potential therapeutic target in cancer treatment.

ITFG1 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. ITFG1 has been shown to interact with the protein tau and has been shown to play a role in the regulation of tau tangles, which are a hallmark of neurodegenerative diseases.

In addition to its potential role as a drug target and biomarker, ITFG1 has also been shown to have several potential therapeutic applications. For example, ITFG1 has been shown to be involved in the regulation of inflammation and has been used as a potential therapeutic target in the treatment of inflammatory diseases.

Conclusion

In conclusion, ITFG1 is a protein that has been identified as a potential drug target and biomarker. Its involvement in GPCR signaling, cell adhesion, and migration, as well as its potential role as a therapeutic target for cancer, neurodegenerative diseases, and autoimmune diseases, make ITFG1 an attractive target for further research and development. Further studies are needed to fully understand the role of ITFG1 in these processes and to develop effective treatments for these diseases.

Protein Name: Integrin Alpha FG-GAP Repeat Containing 1

Functions: Modulator of T-cell function. Has a protective effect in graft versus host disease model (By similarity)

The "ITFG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITFG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets